FDA approves Gilead's hepatitis C drug for expanded use

Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration approved the expanded use of its blockbuster hepatitis C drug, Harvoni.

The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and in patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said in a statement

(Reporting by Rosmi Shaji in Bengaluru; Editing by Anil D'Silva)